Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the firm. Four analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $1.38.
Several research analysts have issued reports on ANTH shares. HC Wainwright restated a “buy” rating and set a $3.00 price target (down previously from $10.00) on shares of Anthera Pharmaceuticals in a report on Thursday, December 29th. Citigroup Inc lowered shares of Anthera Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Thursday, December 29th. Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, January 2nd. Piper Jaffray Companies lowered their price objective on shares of Anthera Pharmaceuticals from $7.00 to $1.35 and set an “overweight” rating for the company in a research note on Thursday, December 29th. Finally, Jefferies Group LLC lowered shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating and lowered their price objective for the company from $5.00 to $1.00 in a research note on Thursday, December 29th.
TRADEMARK VIOLATION NOTICE: “Brokerages Set Anthera Pharmaceuticals Inc (ANTH) Target Price at $1.38” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2017/04/21/anthera-pharmaceuticals-inc-anth-receives-average-rating-of-buy-from-brokerages-updated.html.
An institutional investor recently raised its position in Anthera Pharmaceuticals stock. Abingworth LLP raised its position in shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) by 16.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 512,036 shares of the biopharmaceutical company’s stock after buying an additional 74,042 shares during the period. Anthera Pharmaceuticals comprises 1.5% of Abingworth LLP’s investment portfolio, making the stock its 15th largest position. Abingworth LLP owned 1.22% of Anthera Pharmaceuticals worth $1,531,000 as of its most recent filing with the SEC. 50.87% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Anthera Pharmaceuticals (NASDAQ:ANTH) traded up 3.500% during midday trading on Friday, hitting $0.414. 1,573,509 shares of the company’s stock traded hands. The company has a 50 day moving average price of $0.47 and a 200 day moving average price of $1.29. Anthera Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $4.40. The firm’s market capitalization is $20.95 million.
Anthera Pharmaceuticals (NASDAQ:ANTH) last released its quarterly earnings results on Monday, February 27th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.05. Equities analysts anticipate that Anthera Pharmaceuticals will post ($0.77) earnings per share for the current year.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
Receive News & Ratings for Anthera Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.